Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
BELLUS Health Inc. BLU
$14.49
-$0 (-0.03%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
1838184840.00000000
-
week52high
14.54
-
week52low
6.38
-
Revenue
16000
-
P/E TTM
-64
-
Beta
-0.49466500
-
EPS
-0.66000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 10:59
Описание компании
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 11 авг 2022 г. |
| RBC Capital | Outperform | Outperform | 13 июл 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 24 февр 2022 г. |
| Evercore ISI Group | Outperform | Outperform | 13 дек 2021 г. |
| RBC Capital | Outperform | Outperform | 07 дек 2021 г. |
| Jefferies | Buy | Buy | 23 сент 2022 г. |
| RBC Capital | Outperform | Outperform | 30 сент 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Was This Acquisition a Savvy Play by This Big Pharma Stock?
The Motley Fool
26 апр 2023 г. в 09:00
U.K.-based GSK is buying Canadian biotech Bellus Health for $2 billion. The purchase will include a promising drug candidate for treating chronic cough.
Why Shares of Bellus Health Skyrocketed This Week
The Motley Fool
20 апр 2023 г. в 14:36
Bellus' lead therapy, camlipixant, is being tested against refractory chronic cough. The company is a clinical-stage biotech with no marketed therapies.
Bellus Health (BLU) Stock Up 99% on $2B Buyout Offer From GSK
Zacks Investment Research
19 апр 2023 г. в 11:29
Bellus Health (BLU) gets an offer to be acquired by pharma bigwig, GSK for an approximate total equity value of $2 billion. The stock is up 99%, following the news.
Biopharma stock soars on takeover deal plus more daily small cap and micro cap movers
Proactive Investors
18 апр 2023 г. в 15:06
11:55am: Bellus Health (TSX:BLU), The Lion Electric Company shares make big gains BELLUS Health Inc (Bellus Health (TSX:BLU)) shares shot up 99% to $19.33 on Tuesday after the late-stage biopharmaceutical company announced that it has agreed to be acquired by GSK PLC (LSE:GSK, NYSE:GSK) for US$14.75 per share in cash. As well, shares of The Lion Electric Company (TSX:LEV) shares continued to move higher Tuesday, up 19% to $3.13 following a 12% gain on Monday, as the manufacturer of all-electric medium and heavy-duty vehicles said it officially introduced its new manufacturing factory in Mirabel, Quebec, which will produce lithium-ion batteries for medium and heavy-duty vehicles.
Why BELLUS Health Stock Is Rocketing Higher Today
The Motley Fool
18 апр 2023 г. в 11:33
BELLUS Health and GSK have agreed on a $2 billion buyout agreement. Through this deal, GSK will acquire a late-stage chronic cough medication that could be worth billions in peak sales.